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Abstract
Background: This study aims to identify risk factors and the neurodevelopmental impact of neonatal hyperbilirubinemia
in a limited-resource setting among a refugee and migrant population residing along the Thai-Myanmar border, an
area with a high prevalence of glucose-6-phosphate dehydrogenase-deficiency.
Methods: This is an analytic, observational, prospective birth cohort study including all infants of estimated gestational
age equal to or greater than 28 weeks from mothers who followed antenatal care in the Shoklo Malaria Research Unit
clinics. At birth, a series of clinical exams and laboratory investigations on cord blood will be carried out. Serum
bilirubin will be measured in all infants during their first week of life. All the infants of the cohort will be clinically
followed until the age of one year, including monitoring of their neurodevelopment.
Discussion: The strength of this study is the prospective cohort design. It will allow us to collect information about the
pregnancy and detect all infants with neonatal hyperbilirubinemia, to observe their clinical response under treatment
and to compare their neurodevelopment with infants who did not develop neonatal hyperbilirubinemia. Our study
design has some limitations in particular the generalizability of our findings will be limited to infants born after the
gestational age of 28 weeks onwards and neurodevelopment to the end of the first year of life.
Trial registration: ClinicalTrials.gov ID NCT02361788, registration date September 1st, 2014.
Keywords: Neonatal hyperbilirubinemia, Jaundice, Phototherapy, Infant, Low-resource, Refugee, Migrant, Resource-
limited setting, G6PD deficiency, Neurodevelopment
Background
Clinically significant neonatal hyperbilirubinemia (NH)
is an important cause of neonatal morbidity and mortal-
ity and the most frequent reason for delayed hospital
discharge or readmission in the first week of life world-
wide [1, 2]. Low- and middle-income countries, however,
disproportionately bear the burden of severe NH [1, 3]
especially countries with a high prevalence of glucose-6-
phosphate dehydrogenase (G6PD)-deficiency [4]. In
addition to the difficulty of establishing routine G6PD-
deficiency screening in newborns as recommended by the
World Health Organisation [5] other challenges which im-
pact on NH prevail, including: rhesus sensitization, mater-
nal health-seeking behaviour, availability of neonatal units,
and use of guidelines for early recognition and treatment
of NH. In developing countries, NH is also one of the
main causes of neurodevelopmental impairment in in-
fants, especially in premature infants [1, 3], even though
the harmful consequences of NH could be easily pre-
vented by early detection and phototherapy [6, 7].
A recent meta-analysis of NH in low- and middle-
income countries highlighted the need for more robust
epidemiological studies to identify additional risk factors
that may be particular to these settings [3]. In addition,
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there are no guidelines to prevent and manage NH in
low resources settings. Olusanya, et al. have proposed
adapting existing guidelines from high level income
countries for NH screening in low resource settings [8].
However, as NH is often the result of complex interac-
tions with multiple causes linked to the population and
the environment, the development of context-specific
guidelines may be more appropriate for these popula-
tions particularly affected by NH.
This manuscript summarizes the protocol of an ana-
lytic, observational, prospective birth cohort study which
will identify local risk factors associated with NH in a
limited-resource setting. As far as we are aware this will
be the largest birth cohort study that combines research
on the risk factors of NH and follow-up monitoring up
to one year of life in South East Asia [9–12]. The infor-
mation gathered from this study will be used to improve
and adapt existing guidelines for resource-constrained
environments, help develop locally relevant protocols,
and make evidence-based recommendations on where
and how limited resources can be best allocated to re-
duce the risks and the negative outcomes of NH. At the
time of writing this protocol seven of the eight refugee
camps on the Thai-Myanmar border where the study
will take place do not have access to point of care G6PD




The study primary objective is to determine the risk fac-
tors associated with moderate and severe NH [6]. The
secondary objectives are to: i) determine the incidence
of NH and of prolonged jaundice; ii) compare the SBR
trend and response to phototherapy by risk factors asso-
ciated with moderate and severe NH; iii) determine
whether severe NH impairs neurodevelopment.
Setting
The Shoklo Malaria Research Unit (SMRU) is a recog-
nised field research unit working with the refugee (since
1986) and the migrant populations (since 1998) residing
on the Thai-Myanmar border [13]. SMRU provides free
medical and obstetric care in three clinical sites along
the border. All women are invited to the antenatal care
(ANC) clinic as soon as they are aware of their preg-
nancy. During the first ANC visit a dating ultrasound ac-
curately determines the gestational age of the pregnancy.
This is important in the context of this study because
prematurity is a major risk factor for NH [6]. All women
attending ANC are routinely screened for G6PD (fluor-
escent spot test) and thalassemia, and their ABO group
is determined. They are provided with maternity services
and are encouraged to deliver at the SMRU clinic
although traditionally women birthed at home. Neonates
in need of medical attention are admitted to the special-
care baby unit (SCBU) and older infants to the inpatient
department.
The study will take place in the three SMRU-SCBUs
(established between 2008 and 2009) where local medics
and nurses work under supervision and receive training
by an expatriate doctor. SBR measurement and blue
light phototherapy were introduced in 2009 using the
US National Institute for Health and Care Excellence
Guidelines (NICE) for clinical care of NH [6].
Study design and patient recruitment
The study will be an analytic, observational, prospective
birth cohort study.
All women attending ANC will be provided with infor-
mation about the study during the 3rd trimester of their
pregnancy and provide informed consent for the new-
born if they are willing to participate. Maternal demo-
graphic, medical and obstetric history will be collected
at the time of enrolment. All infants born in an SMRU
birthing facility will be included unless born extremely
premature (defined in this study and other low resource
settings as a gestational age of less than 28 weeks). In
this cohort, the incidence of NH will be determined
(Fig. 1).
Of the women who attended SMRU ANC, approxi-
mately 10% give birth at home and 8% in another hos-
pital. Any infant born outside the SMRU clinic will be
eligible if they present in the first 48 h of life, or if they
present with jaundice from 48 h to 8 days of life.
The study start-up will be staggered to ensure that
each of the teams in the three study clinical sites can op-
erate smoothly and consistently. At each site, the period
of enrolment will last one calendar year. The infants will
be followed up monthly until they reach twelve months
of age. The study recruitment is expected to close on
May 13, 2017.
Study procedures
A timeline of the study procedures is presented in Fig. 2.
At birth, umbilical cord blood will be collected. The use
of umbilical cord blood allows enough blood volume for
several tests including: blood group and Coomb’s test,
G6PD testing, albumin level and genotyping of three dif-
ferent loci (G6PD-deficiency, Southeast Asia Ovalocyto-
sis and Gilbert’s syndrome).
Within the first 24 h a physical examination including
anthropometry measurements and clinical jaundice
evaluation will be performed as part of routine neonatal
care. The mother will be questioned about breastfeeding,
use of medicines or preparations for the infant, and the
use of naphthalene creams or balls. The NICE Guide-
lines for clinical care of NH, defining, for each
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gestational age, SBR measurement and treatment thresh-
olds for moderate and severe NH, will be used in this
study to minimize misclassification.
The follow-up schedule will consist of 4 visits in the
first week of life, weekly visits until 1 month of age and
then monthly visits until 12 months of age (Fig. 2). To
ensure adequate attendance to follow-up, each appoint-
ment date will be reported in the participant’s medical
booklet and parents of the participant who missed an
appointment will be called by phone or visited by a
health worker. In addition, parents accompanying the
child will be compensated for loss of work and travel ex-
penses at an appropriate local rate.
During the visits, routine examination will include an-
thropometric measurements and physical examination.
Laboratory examination will include regular haematocrit
(Hct) testing, G6PD testing repeated at 1 month and
haemoglobin (Hb) typing at 1 year of age. Quantitative
spectrophotometric assay will be carried out in a sub-
sample of females to characterize the enzymatic activity
of heterozygous subjects and the associated risk of de-
veloping NH.
The infant neurodevelopment will be assessed using
the Shoklo Developmental Test at 3, 6, and 12 months
[14]. Scoring will be based on a pass/fail system for each
item of the test; the global score of the test will be ob-
tained by adding up all the passed scores of the follow-
ing categories; eye-hand coordination, gross motor,
social and speech development. Tone and behaviour
during the test will be assessed and scored separately by
circling the most appropriate pre-coded diagram (for
tone) or description (for behaviour).
Fig. 1 Enrolment and eligibility. The figure presents the enrolment eligibility criteria in pregnancy, at birth (for those born in SMRU settings) and
in the first week of life (for those born at home or another hospital)
Fig. 2 Study procedure timeline. Timeline of the different clinical and laboratory procedures from birth to 1 year of age. * G6PD deficiency,
Southeast Asian Ovalocytosis and Gilbert’s syndrome. Del: Delivery, W: week, M: month
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Clinical care
The clinical and research experience of the staff in con-
junction with reliable laboratory services and treatment
facilities will permit an efficient management of NH.
Each SBR measurement will be immediately plotted on a
jaundice treatment graph specific for the gestational age
(NICE graph) to assess the need for additional follow-up
visits, phototherapy, or referral to a tertiary hospital. In-
fants requiring an exchange transfusion (SBR >
550 μmol/L at any time, with or without clinical signs)
will be transferred to the local Thai Hospital in Mae Sot
(60 km away). In case of prolonged jaundice (more than
21 days) there will be further investigations [6].
During the neonatal period, weight will be regularly
measured and if there is ≥ 10% weight loss compared to
the birth-weight the infant will be examined carefully for
any underlying causes and necessary care will com-
mence. All medical conditions including anaemia, de-
fined as Hct < 33% will be treated according to
standardized guidelines used in this area (Burmese
Border Guidelines [15]).
Outcomes
The primary outcome of this study will be to measure
the relative risk of factors associated with moderate and
severe NH in infants born at SMRU and to calculate
their population-attributable fraction. The secondary
outcomes will be to: i) determine the incidence of NH
and of prolonged jaundice; ii) measure the changes in
the trend of consecutive SBR and the duration of photo-
therapy according to the risk factors; iiia) compare the
clinical condition (anaemia incidence, stunting preva-
lence) between severe and moderate NH, and normal
bilirubinaemia in the first year of life; iiib) compare the
neurocognitive developmental, tone and behaviour total
scores at one year of life between severe and moderate
NH, and normal bilirubinaemia.
Sample size
A convenience sample including all births within a one
year timeframe at each site was chosen. Based on previ-
ous SMRU studies, it is assumed that most mothers will
agree to participate in this study and that 15% of infants
will be lost to follow-up before completion of the study.
More than 90% of women in the area attend ANC. In
2014 more than 80% of women who attended ANC care
birthed at SMRU clinics (2040 infants born alive of
28 weeks or more gestational age). It is expected that
1734 infants will be included in the study.
With a total sample size of 1734 infants and an ap-
proximate prevalence for NH of 15%, the statistical
power (two-sided 95% confidence interval) of a relative
difference in the risk of NH of 1.5 fold and 2-fold, in
association with a binary risk factor with a prevalence of
10, 20 or 50%, is presented (Table 1).
Ethical considerations
The population served by the SMRU clinics are predom-
inantly migrant workers and refugees. These individuals
have lower levels of income and education, poorer health
outcomes, and migratory housing arrangements. SMRU
has been serving this population for over 30 years and
has experience of working with vulnerable populations.
SMRU medics, nurses and health workers are recruited
from the same areas as the patient population and are
sensitive to their needs. All communication is conducted
in the preferred language of the patient. We ensure that
participation is voluntary and that it is clearly under-
stood that participation in the study can be ceased at
any time without effect to the care provided.
Trained counsellors will seek the mother’s consent
after the patient information sheet has been discussed.
All queries from the mothers will be answered and those
who agree will sign the consent form. Trained personnel
carry out all capillary and venous blood taking to reduce
infant’s discomfort from these procedures. All data col-
lected will be treated confidentially and stored securely.
Data collection and analysis
Data will be collected on pre-coded forms and stored in
a purpose-designed Microsoft Access database. A
hypothesised causal diagram for how factors associated
with NH may be connected will be constructed. The in-
cidence of NH and corresponding 95% confidence inter-
val will be calculated within the population of newborns
born in the SMRU clinics only; eligible newborns born
outside SMRU facilities will be excluded from the inci-
dence analysis as they might falsely increase the inci-
dence of NH in this population. Following this,
univariate and multivariate logistic regressions will be
performed to identify risk factors for NH. Stepwise logis-
tic regression modelling with backward elimination will
be performed on the subset of candidate risk factors se-
lected based on p-value < 0.10 in the univariate regres-
sion analyses. Key confounders, identified a priori in the
causal diagram will be forced into the model. To esti-
mate the association between NH and neurocognitive
Table 1 Statistical power calculations
Relative risk (RR) for NH associated with
binary risk factor
RR = 1.5 RR = 2.0
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score, multivariate linear regression will be performed
with adjustment for the confounders identified in the
causal diagram. Pre-planned subgroup analysis will be
conducted in order to identify risk factors associated
with moderate and severe NH and estimate the associ-
ation between NH and neurodevelopment (measured as
a continuous neurocognitive score). The description of
the clinical course will be supported by SBR measure-
ment tracking recorded on the treatment graph. SBR
measurements will be modelled to understand factors
impacting on trends [6]. A senior biostatistician will
oversee the statistical analyses.
Discussion
There are several strengths to the proposed protocol.
First, it is a prospective birth cohort study. The active
screening for NH will help early detection, treatment
and severity categorization of the NH. Moreover, it will
allow the comparison of neurodevelopmental scores at
1 year of age between infants with and without NH, an
important and unique feature of the study.
Secondly, the collection of umbilical cord blood will
provide valuable information otherwise rarely available
on possible NH predisposing factors, such as the pres-
ence of a UGT1A1 polymorphisms (Gly71Arg and
TATA promotor) associated with or without Gilbert’s
and/or Crigler-Najjar syndrome [16], or Southeast Asian
Ovalocytosis [17, 18].
G6PD-testing (fluorescent spot test) performed on the
cord blood can be falsely normal because of the high
number of reticulocytes and young red blood cells with
a higher level of activity or when haemolysis is present
[19]. For this reason the fluorescent spot test will be re-
peated in all infants at the age of one month. This will
give valuable information about the reliability of one of
the most frequently used screening tests in resource-
constrained settings where the test is most often per-
formed only at birth.
G6PD-deficiency is very common among the refugee
and migrant populations living on the Thai-Myanmar
border [20]. This study will quantify the contribution of
G6PD-deficiency to the incidence and severity of NH in
these populations. It will confirm clinical experience that
a high proportion (25%) of newborns requiring photo-
therapy are G6PD-deficiency and that these newborns
require a longer phototherapy duration [21]. Further-
more it will account for a common practice in these
populations [22]: the use of naphthalene creams or balls
containing naphthalene stored with infant clothes. There
is a risk for the infant of naphthalene skin absorption,
inhalation or accidental ingestion, which is a known
cause of haemolysis in G6PD deficient patients [23, 24].
As eligible babies are from mothers who followed
ANC and the majority of mothers give birth in SMRU
facilities, detailed pregnancy information will be avail-
able. In Asia, ABO blood group incompatibility and
G6PD-deficiency are the two most commonly known
causes of NH [1].
On the negative side, women who choose not to at-
tend ANC or are unable to attend will be omitted from
this study. These women are known to be at higher risk
of complications in labour and their offspring might
need more medical attention [25]. Nonetheless there is a
possibility for infants born outside the SMRU birth units
and presenting within 48 h of life (or up to 8 days of life
in infants with NH) to be included in the study and to
be followed up until one year of age.
This protocol has some additional identifiable limita-
tions. First, inclusion of infants is limited to those born
after the gestational age of 28 weeks thus potentially re-
ducing the overall incidence of NH. Severely preterm in-
fants are at risk of severe NH and neurological
impairment due to NH but survival in resource con-
strained settings before 28 weeks is extremely rare as
ventilator assistance is unavailable. Infants who are born
before 28 weeks are given supportive care and excluded
from this analysis, as described and recommended by
Turner et al. [21]. The estimation of gestation with ultra-
sound before 14 weeks of pregnancy is reliable and the
quality of ultrasound service in the SMRU clinics is high
[26]. If the mother attends ANC after the 24 weeks of
gestational age the next best estimate will be chosen
from the Dubowitz test [27] or last menstrual period if
known.
A second limitation of this study is that the follow-up
will last only one year and no auditory tests or magnetic
resonance imaging are available. It means that the diag-
nosis of kernicterus will not be explored in as much de-
tail as is possible in resource rich settings [28].
Kernicterus is most usually characterized by choreoathe-
toid cerebral palsy, impaired upward gaze, and sensori-
neural hearing loss whereas cognition is relatively spared
[28]. There is also controversial discussion about the re-
lationship between NH and developmental delay, cogni-
tive impairment or behavioural disorders [29]. These will
only become evident when the child is older than one
year of age. Strict definitions of moderate and severe NH
and treatment protocols will help minimize these limita-
tions [6].
Interpretation of the data must consider the use of dif-
ferent types of phototherapy in the SMRU clinics (bulbs
and Light-emitting diode units). Differences in irradiance
will be recorded to help reduce bias in the interpretation
of the results. The Bilirubin Induced Neurological Dys-
function (BIND) Score [30] has recently been validated
for resource-limited settings in Africa. Unfortunately,
the BIND score was not included in this study protocol.
However medical staff working in the SCBU have
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learned to systematically describe in their ‘daily observa-
tion sheet’ the neonate’s tone, alertness, movements and
sucking behaviour. This should be enough to reconsti-
tute the BIND score, at least partially, to evaluate and
categorize the neurological evolution of the neonate dur-
ing their hospitalization in the SCBU.
Conclusion
It is expected that the study will confirm that neonatal
jaundice is a risk factor for neonatal mortality and long-
term morbidity, and raise awareness of the problem. It
will provide evidence to develop appropriate clinical and
public health guidelines to address the problem, thereby
improving maternal and child health care. We expect
that the observations and recommendations resulting
from the study can be used in other parts of South-East-
Asia as well, especially in Myanmar.
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